JUPITER, Fla., May 2, 2014 /PRNewswire/ -- Charleston Laboratories, Inc., an emerging specialty pharmaceutical company focused on the research and development of novel pain products, today announced the publication of an abstract and presentation of a poster entitled, “Demonstration of the safety and efficacy of CL-108 for moderate-to-severe pain with reduction of opioid-induced nausea and vomiting,” at the 2014 Annual Meeting of the American Pain Society being held in Tampa, Florida this week. The poster will be author attended on Friday May 2nd from 8:45am to 10:15am by Dr. Bernard Schachtel, Chief Scientific Officer of Charleston Laboratories.
This abstract was published in the April 2014 issue of the Journal of Pain, the official journal of the American Pain Society.
Charleston Laboratories, Inc.
Charleston Laboratories, Inc. is a privately held, specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce the burdensome side effects related to opioid analgesics and other products. Charleston’s product pipeline currently addresses Opioid-Induced Nausea and Vomiting (OINV), Postoperative Nausea and Vomiting (PONV), Chemotherapy-Induced Nausea and Vomiting (CINV), Radiation-Induced Nausea and Vomiting (RINV), and Migraine-Induced Nausea and Vomiting (MINV). Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that reduce the burdensome side effects related to opioid analgesics and other products.
SOURCE Charleston Laboratories, Inc.
Help employers find you! Check out all the jobs and post your resume.
